September 26, 2020

The Niche

Knoepfler lab stem cell blog

Search Results for: covid-19

4 min read

Another week and more great papers and interesting news in the regenerative medicine sphere including COVID-19 updates, stem cells for vision, and more. Rebuilding Corneas With Stem Cells Stem cell-based regenerative medicine arguably has shown the most promise for vision loss. A PR from Massachusetts Eye and Ear says: Doctors rebuild damaged corneas using patients’ own own stem cells for first time in US. This is interesting work. The autologous transplant method is called “‘cultivated autologous limbal epithelial cell transplantation’ (CALEC).” It involves taking …Read More

8 min read

Introduction to CAR-T cells CAR-T cells are an exciting cutting-edge technology that has been garnering great interest including in the stem cell field. Potential therapeutic uses of CAR-T, which stands for Chimeric Antigen Receptor T-Cells (CAR-T), are being studied in clinical trials as immunotherapies to potentially fight cancer as well as many other diseases by using one’s own immune system. The process of CAR-T therapy (see diagram below) starts off with the collection of the patient’s own T-cells through apheresis. The cells are then …Read More

5 min read

The FTC has sharply increased its oversight activities against stem cell and regenerative clinic firms. These new actions include quite a few warning letters. Here is the FTC database for COVID-19-related warning letters. Note that recently the FTC added a new, helpful option to view all of its warning letters here. It’s a good source of information. FTC warns many stem cell & related firms From USA Today, Brent Schrotenboer had this recent piece Stem cell companies sell hope with unproven medicine for COVID-19. Some …Read More

6 min read

The FDA and its CBER branch have been doing a good job overall in the last 3+ years to tackle the unproven stem cell clinic problem, but lately on the stem cells for COVID-19 front there is reason for real concern. I believe the agency is taking on major risk overall by clearing a vast number of cell therapy trials for COVID-19 mostly without much data, but the clearance of a few programs by for-profit stem cell clinics is especially problematic in my view. FDA on …Read More